Sunday, June 1, 2025
6/1/2025
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy - Targeting post-translational modifications of B7-H4 in carcinogenesis and therapy The goal of this project is to determine the impact of interplay between glycosylation and ubiquitination of B7-H4 in breast carcinogenesis and anti-breast cancer therapy. B7-H4, also known as V-set domain containing T cell activation inhibitor 1 (VTCN1), acts as an immune checkpoint protein whose local abnormal accumulation is correlated with poor prognosis of various types of cancers including triple negative breast cancer (TNBC). While a current TCGA study suggests the critical role of B7-H4 in conferring tumor sensitivity to chemotherapy drugs and immune checkpoint inhibitors, how B7-H4 is regulated and how its deregulation contributes to breast carcinogenesis and tumor drug response remain unknown. Results from our recent purification of the B7-H4 protein complex revealed that 2 critical enzymes, AMFR and STT3 complex, tightly interact with and regulate B7-H7. While the E3 ubiquitin ligase AMFR catalyzes ubiquitination of B7-H4 followed by degradation, we observed that glycosylation of B7-H4 protein by the STT3 complex (a glycosyltransferase) results in the stabilization of B7-H4 and inhibition of doxorubicin-induced immunogenic cell death (ICD). Elevation of B7-H4 levels due to enhanced B7-H4 glycosylation counteracts B7-H4 ubiquitination, which in turn suppresses endoplasmic reticulum stress-mediated phagocytosis in response to chemotherapy drugs, a critical step in triggering mass tumor eradication by ICD. We further demonstrated that blockade of B7-H4 glycosylation by NGI-1, a novel protein glycosylation inhibitor, significantly enhances B7-H4 ubiquitination and subsequent degradation, resulting in promotion of tumor killing efficacy due to increased phagocytosis by dendritic cells and their capacity to elicit CD8+ interferon-γ-producing T cell responses. In this project, we plan to test the hypothesis that deregulation of B7-H4 by the crosstalk between glycosylation and ubiquitination promotes TNBC tumor evasion from chemotherapy and blockade of B7-H4 glycosylation by NGI-1 could be a new strategy for anti-TNBC treatment. We propose the following specific aims to pursue this goal: (1) to determine the mechanism by which interplay between glycosylation and ubiquitination regulates B7-H4-orchestrated phagocytosis; (2) to determine the physiological relevance of STT3-mediated glycosylation and AMFR-facilitated ubiquitination in B7-H4-mediated ICD in response to chemotherapy drugs; and (3) to determine the clinical relevance of blockade of B7-H4 glycosylation by NGI-1 in anti-TNBC treatment using various preclinical murine models.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).